Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details)

v3.25.4
Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Information [Line Items]      
Revenue € 1,186,282 € 1,104,036 € 1,085,354
Cost of sales 842,406 801,717 745,461
Gross Profit 343,876 302,319 339,893
Other operating income 8,244 9,091 10,423
Selling and Marketing expenses 28,219 24,853 24,978
Research and Development expenses 25,436 31,668 35,672
General and Administrative expenses 99,664 93,747 88,946
Operating Profit 198,801 161,142 200,720
Amortization and Depreciation and Impairment of PPE 88,565 80,652 78,480
External Customers      
Segment Information [Line Items]      
Revenue 1,186,282 1,104,036 1,085,354
Adjustments, Eliminations and Unallocated Items      
Segment Information [Line Items]      
Revenue (135,064) (191,379) (168,790)
Cost of sales (119,773) (168,746) (140,196)
Gross Profit (15,291) (22,633) (28,594)
Other operating income (190) 57 (223)
Selling and Marketing expenses 1,960 415 60
Research and Development expenses (127) 1,068 599
General and Administrative expenses 13,640 13,530 10,998
Operating Profit (30,954) (37,589) (40,474)
Amortization and Depreciation and Impairment of PPE 394 1,097 (661)
Adjustments, Eliminations and Unallocated Items | Inter-Segment      
Segment Information [Line Items]      
Revenue (135,064) (191,379) (168,790)
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Segment Information [Line Items]      
Revenue 1,040,337 937,779 881,337
Cost of sales 712,187 668,997 591,107
Gross Profit 328,150 268,782 290,230
Other operating income 8,434 8,926 10,630
Selling and Marketing expenses 23,568 20,847 20,970
Research and Development expenses 19,585 23,292 27,653
General and Administrative expenses 73,005 67,933 64,658
Operating Profit 220,426 165,636 187,579
Amortization and Depreciation and Impairment of PPE 84,687 75,747 75,320
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 1,038,174 933,742 879,288
Biopharmaceutical and Diagnostic Solutions | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 2,163 4,037 2,049
Engineering | Operating Segments      
Segment Information [Line Items]      
Revenue 281,009 357,636 372,807
Cost of sales 249,992 301,466 294,550
Gross Profit 31,017 56,170 78,257
Other operating income   108 16
Selling and Marketing expenses 2,691 3,591 3,948
Research and Development expenses 5,978 7,308 7,420
General and Administrative expenses 13,019 12,284 13,290
Operating Profit 9,329 33,095 53,615
Amortization and Depreciation and Impairment of PPE 3,484 3,808 3,821
Engineering | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 148,108 170,294 206,066
Engineering | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 132,901 187,342 166,741
Total Segments | Operating Segments      
Segment Information [Line Items]      
Revenue 1,321,346 1,295,415 1,254,144
Cost of sales 962,179 970,463 885,657
Gross Profit 359,167 324,952 368,487
Other operating income 8,434 9,034 10,646
Selling and Marketing expenses 26,259 24,438 24,918
Research and Development expenses 25,563 30,600 35,073
General and Administrative expenses 86,024 80,217 77,948
Operating Profit 229,755 198,731 241,194
Amortization and Depreciation and Impairment of PPE 88,171 79,555 79,141
Total Segments | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 1,186,282 1,104,036 1,085,354
Total Segments | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue € 135,064 € 191,379 € 168,790